Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Sarcoma, Kaposi 4Leukemia, Lymphocytic, Chronic, B-Cell 2Epstein-Barr Virus Infections 2Cytomegalovirus Infections 2Acquired Immunodeficiency Syndrome 2Sarcoma 1Multi-centric Castleman's Disease 1Lymphoproliferative Disorders 1Lymphoma 1Leukemia 1Immune Reconstitution Inflammatory Syndrome 1Herpes Simplex 1Glioblastoma 1Fatigue Syndrome, Chronic 1Fatigue 1Castleman Disease 1

Interventions

dacetuzumab 6blinatumomab 6Rituximab 4Epoetin Alfa 4Lenalidomide 3Dexamethasone 3Darbepoetin alfa 3Cyclophosphamide 3Bortezomib 3Therapeutics 2Everolimus 2Early Intervention, Educational 2Alemtuzumab 2venetoclax 1vandetanib 1tirbanibulin 1tetulomab tetraxetan lu-177 1ponatinib 1plerixafor 1pembrolizumab 1pegaspargase 1isatuximab 1imetelstat 1ibrutinib 1fludarabine 1ficlatuzumab 1ferrous sulfate 1ferric gluconate 1ferric carboxymaltose 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoproliferative Disorders × Valganciclovir × Clear all
NCT03397706 2025-03-20

Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies

Viracta Therapeutics, Inc.

Phase 1/2 Completed
64 enrolled 31 charts
Lymphoid

Lymphoproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡